Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLKW), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics Inc (OTLKW) is a biopharmaceutical innovator advancing ophthalmic treatments for conditions like wet age-related macular degeneration (wet AMD). This page serves as the definitive source for verified company updates, offering investors and healthcare professionals timely access to critical developments.
Find curated press releases covering regulatory milestones, clinical trial progress, and strategic partnerships. Our repository includes updates on the company’s EU/UK-approved bevacizumab formulation, financial filings, and research breakthroughs—all organized for efficient tracking of this clinical-stage leader.
Regularly refreshed with official announcements, this resource helps stakeholders monitor OTLKW’s progress in addressing unmet ophthalmic needs. Bookmark this page to stay informed about pipeline advancements and market expansions directly from the source.
Outlook Therapeutics (Nasdaq: OTLK) reported fiscal 2025 results for the year ended September 30, 2025. The company recorded a net loss of $62.4 million ($1.79 per share) and $1.4 million of revenue from initial European sales of LYTENAVA in June 2025. Gross profit was reduced by increased reserves for short-dated inventory from UK shipments. Operating expenses fell year-over-year driven by lower R&D after completion of NORSE Eight, offset by higher SG&A from the European launch. Cash and equivalents were $8.1 million at September 30, 2025, plus $14.9 million net ATM proceeds received after the period. The FDA PDUFA goal date for ONS-5010 is December 31, 2025.
Outlook Therapeutics (Nasdaq: OTLK) announced that CEO Bob Jahr will participate in a live fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET.
Management is also available for one-on-one in-person meetings with qualified, registered investors at the conference. A live webcast will be available on the company Investors > Events page and the replay will be archived for 90 days after the event.
Outlook Therapeutics (Nasdaq: OTLK) announced the U.S. FDA has accepted the resubmission of its Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD).
The FDA considers the resubmission a complete, Class 1 response to the August 27, 2025 action letter, initiating a 60-day review and setting a PDUFA goal date of December 31, 2025. If approved, ONS-5010 will be branded LYTENAVA for treatment of wet AMD.
Outlook Therapeutics (Nasdaq: OTLK) re-submitted its Biologics License Application (BLA) for ONS-5010 to the U.S. FDA on Nov 3, 2025 after receiving official minutes from an FDA Type A meeting held in September 2025. ONS-5010 is an investigational ophthalmic bevacizumab formulation proposed to be branded LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).
The company said the resubmission is intended to resolve the outstanding issue identified in a Complete Response Letter (CRL) dated August 2025 and that it is accelerating commercial efforts in Europe while positioning for a potential near-term U.S. approval.
Outlook Therapeutics (NASDAQ: OTLK) has completed its Type A Meeting with the FDA regarding the Complete Response Letter (CRL) for ONS-5010, its investigational ophthalmic bevacizumab formulation for wet AMD treatment. The meeting focused on discussing the CRL received on August 27, 2025, concerning the company's biologics license application (BLA).
Following the FDA discussion, Outlook Therapeutics plans to resubmit its BLA before the end of 2025, after reviewing the agency's feedback and meeting minutes. CEO Bob Jahr described the FDA meeting as productive and reaffirmed the company's commitment to providing a safe and effective ophthalmic bevacizumab treatment option for wet AMD patients in the U.S.
Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, will present at the EURETINA Innovation Spotlight during the 25th EURETINA Congress. The presentation titled "Optimising the treatment of retinal disease" will be delivered by CEO Bob Jahr on September 3, 2025 at 16:10 PM CEST / 10:10 AM EDT in Paris, France.
Outlook Therapeutics (Nasdaq: OTLK) has requested a Type A Meeting with the FDA following a Complete Response Letter (CRL) regarding their ONS-5010 biologics license application. The CRL, issued on August 27, 2025, acknowledged that the NORSE TWO pivotal trial met safety and efficacy endpoints but recommended additional confirmatory evidence for the wet AMD treatment.
ONS-5010 is an investigational ophthalmic formulation of bevacizumab designed to provide a regulated alternative to compounded bevacizumab, which has been used off-label as a first-line wet-AMD treatment. The Type A meeting aims to clarify the specific confirmatory evidence required by the FDA for approval.
Outlook Therapeutics (NASDAQ: OTLK) announced that the FDA has issued a Complete Response Letter (CRL) for ONS-5010/LYTENAVA™ (bevacizumab-vikg), their wet AMD treatment candidate. The FDA cannot approve the application in its current form due to lack of substantial evidence of effectiveness.
The CRL highlighted that while the NORSE TWO trial met its primary endpoint, the NORSE EIGHT trial did not, leading to the FDA's recommendation for additional confirmatory efficacy evidence. Despite this setback in the U.S., LYTENAVA™ has already received Marketing Authorization in the European Union and UK, and has been commercially available in Germany and UK since June 2025 as the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment.
Outlook Therapeutics (NASDAQ: OTLK) reported its Q3 FY2025 financial results and achieved significant milestones. The company recorded its first commercial sales of LYTENAVA™ (bevacizumab gamma) in Europe, marking its transition to a commercial-stage company. For Q3, OTLK reported revenue of $1.5 million and a net loss of $20.2 million ($0.55 per share).
The company has a crucial PDUFA date of August 27, 2025, for ONS-5010/LYTENAVA™ FDA approval in the United States. LYTENAVA™ is now commercially available in Germany and UK for wet AMD treatment, with first patients already dosed. The company ended the quarter with cash and equivalents of $8.9 million.
Outlook Therapeutics (NASDAQ: OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, announced its participation in the 8th Annual OIS Retina Innovation Summit. The company's CEO, Bob Jahr, will present during the Innovation Showcase session on July 29, 2025, from 8:35 – 9:35 AM PT in Long Beach, California.
